


RealRate

PHARMACEUTICAL 2018

## Travere Therapeutics Inc. Rank 78 of 349









PHARMACEUTICAL 2018



## RealRate

Travere Therapeutics Inc. Rank 78 of 349

The relative strengths and weaknesses of Travere Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Travere Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 180% points. The greatest weakness of Travere Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 21%, being 299% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	325,807
Cost of Goods Sold	0
Intangible Assets	185,753
Liabilities, Current	85,668
Liabilities, Non-Current	2,472
Other Assets	5,556
Other Compr. Net Income	-525
Other Expenses	30,595
Other Liabilities	139,072
Other Net Income	-4,572
Property and Equipment	3,230
Research and Development	78,168
Revenues	154,937
Selling, General and Administrative Expense	101,333

Output Variable	Value in 1000 USD
Assets	520,346
Liabilities	227,212
Expenses	210,096
Stockholders Equity	293,134
Net Income	-59,731
Comprehensive Net Income	-59,994
Economic Capital Ratio	21%

